7JN Stock Overview
Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
+ 1 more risk
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.079 |
| 52 Week High | UK£0.17 |
| 52 Week Low | UK£0.077 |
| Beta | 2.14 |
| 11 Month Change | -6.51% |
| 3 Month Change | -41.91% |
| 1 Year Change | -20.60% |
| 33 Year Change | -22.55% |
| 5 Year Change | n/a |
| Change since IPO | -14.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7JN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.6% | 1.4% | 0.8% |
| 1Y | -20.6% | -18.4% | 9.1% |
Return vs Industry: 7JN underperformed the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: 7JN underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 7JN volatility | |
|---|---|
| 7JN Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7JN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7JN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 15 | Jeremy Skillington | www.poolbegpharma.com |
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Poolbeg Pharma PLC Fundamentals Summary
| 7JN fundamental statistics | |
|---|---|
| Market cap | €43.45m |
| Earnings (TTM) | -€5.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.3x
P/E RatioIs 7JN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7JN income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£4.38m |
| Earnings | -UK£4.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0088 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7JN perform over the long term?
See historical performance and comparison